Béata Juzyna
About
Béata Juzyna is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Béata Juzyna has authored 25 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Surgery and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Béata Juzyna's work include Colorectal and Anal Carcinomas (7 papers), Colorectal Cancer Surgical Treatments (6 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Béata Juzyna is often cited by papers focused on Colorectal and Anal Carcinomas (7 papers), Colorectal Cancer Surgical Treatments (6 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Béata Juzyna collaborates with scholars based in France, United States and Slovakia. Béata Juzyna's co-authors include Thierry Conroy, Olivier Bouché, Valérie Boige, Pierre-Luc Etienne, S. Gourgou-Bourgade, Isabelle Martel‐Lafay, Méher Ben Abdelghani, Jean‐Yves Douillard, Laurent Bedenne and Marie‐Pierre Galais and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.
In The Last Decade
Béata Juzyna
25 papers receiving 760 citations
Hit Papers
Peers
Béata Juzyna
Vaneja Velenik Slovenia
Hideo Baba Japan
M Meehan United Kingdom
Vera Oppedijk Netherlands
T. Crosby United Kingdom
R. Innocente Italy
B. Burmeister Australia
N. Barbet France
Soichi Fumita Japan
Calin Radu Sweden
Citations per year, relative to Béata Juzyna Béata Juzyna (= 1×)
peers
Vaneja Velenik
Countries citing papers authored by Béata Juzyna
Since
Specialization
Citations
This map shows the geographic impact of Béata Juzyna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Béata Juzyna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Béata Juzyna more than expected).
Fields of papers citing papers by Béata Juzyna
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Béata Juzyna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Béata Juzyna. The network helps show where Béata Juzyna may publish in the future.
Co-authorship network of co-authors of Béata Juzyna
This figure shows the co-authorship network connecting the top 25 collaborators of Béata Juzyna. A scholar is included among the top collaborators of Béata Juzyna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Béata Juzyna. Béata Juzyna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fizazi, Karim, Gwénaël Le Teuff, Aude Fléchon, et al.. (2024). Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. 42(28). 3270–3276.
2.
Mollévi, Caroline, Sophie Gourgou, Christophe Borg, et al.. (2023). Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis. European Journal of Cancer. 186. 151–165.
3.
Touraine, Célia, et al.. (2023). When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials. BMC Medical Research Methodology. 23(1). 36–36.
4.
Winter, Audrey, Thierry Conroy, Béata Juzyna, et al.. (2022). Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial. Quality of Life Research. 32(3). 669–679.
5.
Conroy, Thierry, et al.. (2021). Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials. Quality of Life Research. 31(5). 1359–1370.
6.
Sigel, Keith, Mengxi Zhou, Tinaye Mutetwa, et al.. (2021). Gemcitabine plus nab‐paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. Seminars in Oncology. 48(1). 69–75.
7.
Mollévi, Caroline, C. Bourgier, Thierry Conroy, et al.. (2020). Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results. Quality of Life Research. 30(1). 91–103.
8.
Mollévi, Caroline, et al.. (2020). Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17. BMC Medical Research Methodology. 20(1). 223–223.
9.
Boige, Valérie, Caroline Mollévi, Sophie Gourgou, et al.. (2019). Impact of single‐nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD‐12/PRODIGE‐2 phase III trial. International Journal of Cancer. 145(11). 3163–3172.
10.
Mollévi, Caroline, Sophie Gourgou, Marie‐Pierre Galais, et al.. (2017). Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer. European Journal of Cancer. 84. 239–249.
11.
Robert, Marie, Marta Jarlier, Sophie Gourgou, et al.. (2017). Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4). Oncology. 93(6). 367–376.
12.
Edeline, Julien, Franck Bonnetain, J. Watelet, et al.. (2017). Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. Annals of Oncology. 28. v617–v617.
13.
Lévy, Antonin, D. Azria, Jean‐Pierre Pignon, et al.. (2015). Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial. Radiotherapy and Oncology. 114(3). 415–416.
14.
Anota, Amélie, Thierry Conroy, S. Gourgou-Bourgade, et al.. (2015). Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial. Medical Decision Making. 36(5). 615–628.
15.
Gérard, Jean‐Pierre, Emmanuel Chamorey, S. Gourgou-Bourgade, et al.. (2015). Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiotherapy and Oncology. 115(2). 246–252.
16.
Conroy, Thierry, Marie‐Pierre Galais, Jean‐Luc Raoul, et al.. (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. The Lancet Oncology. 15(3). 305–314.
17.
Ducreux, Michel, Marc Giovannini, Charlotte Baey, et al.. (2014). Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial. Digestive and Liver Disease. 46(10). 950–955.
18.
Robert, Marie, Marta Jarlier, Thierry Conroy, et al.. (2014). Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma (MPC) treated with FOLFIRINOX or gemcitabine (gem) in a randomized phase III study (ACCORD11/PRODIGE4).. Journal of Clinical Oncology. 32(15_suppl). 4115–4115.
19.
François, Éric, D. Azria, S. Gourgou-Bourgade, et al.. (2014). Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: Tolerance and efficacy. Radiotherapy and Oncology. 110(1). 144–149.
20.
Deutsch, Éric, C. Lemanski, Jean‐Pierre Pignon, et al.. (2013). Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Annals of Oncology. 24(11). 2834–2838.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Vaneja Velenik Breakdown of academic impact, for papers by Hideo Baba Breakdown of academic impact, for papers by M Meehan Breakdown of academic impact, for papers by Vera Oppedijk Breakdown of academic impact, for papers by T. Crosby Breakdown of academic impact, for papers by R. Innocente Breakdown of academic impact, for papers by B. Burmeister Breakdown of academic impact, for papers by N. Barbet Breakdown of academic impact, for papers by Soichi Fumita Breakdown of academic impact, for papers by Calin Radu